DNLI$18.71
Chart
Performance
Key Stats
AI DNLI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralDenali Therapeutics shows potential in its pipeline, but current financial performance and technical indicators suggest a neutral outlook. Further developments in clinical trials and market adoption are critical for a stronger rating.
Thematic
Denali Therapeutics operates in the growing biopharmaceutical sector, focusing on neurodegenerative and lysosomal storage diseases, areas with significant unmet medical needs and strong research interest.
Fundamental
Denali Therapeutics exhibits negative earnings and revenue trends, with substantial operating expenses and a significant cash burn rate. While cash reserves are present, sustained losses impact its fundamental strength.
Technical
Denali Therapeutics' stock is trading below its key moving averages and exhibits mixed signals from oscillators, suggesting a neutral short-to-medium term trend. A break above resistance levels is needed to confirm a bullish shift.
| Factor | Score |
|---|---|
| Neurodegenerative Disease Therapeutics | 85 |
| Lysosomal Storage Disease Treatments | 80 |
| Biotechnology Innovation | 70 |
| Regulatory Environment | 65 |
| Partnerships and Collaborations | 75 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 70 |
| Balance Sheet Health | 90 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 50 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Analyst Buy Consensus
The average analyst price target for Denali Therapeutics (DNLI) is $32.19, indicating a significant potential upside of 132.74% from the current price. Analysts have a strong buy consensus, with 19 buy ratings and no hold or sell recommendations.
Robust Liquidity Position
Denali Therapeutics has a strong current ratio of 8.46, suggesting a solid ability to meet its short-term obligations. The company also holds approximately $1.19 billion in cash, cash equivalents, and marketable securities as of December 31, 2024.
Bearish Points (7)
Consistent Net Losses
Denali Therapeutics has consistently reported net losses, with a net loss of $422.8 million for the year ended December 31, 2024. The company currently has negative EPS of -2.67.
Lack of Current Revenue
The company has reported zero revenue in the trailing twelve months ending March 31, 2025, and significant year-over-year decreases in collaboration revenue due to option exercises by partners.
Calendar
July 2025
30
Next Earnings Date
H: $-0.43
A: $-0.74
L: $-0.93
H: 50.00M
A: 5.64M
0Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Seasonals
Price Target
32.19 USD
The 39 analysts offering 1 year price forecasts for DNLI have a max estimate of 45.00 and a min estimate of 24.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major biopharmaceutical company with a strong focus on neuroscience, including approved therapies for Alzheimer's disease (Leqembi, Aduhelm) and Multiple Sclerosis (MS), and a pipeline for various neurodegenerative diseases. Has also engaged in partnerships with Denali Therapeutics.
Weight: 90
Leading pharmaceutical company with significant investment and a pipeline in Alzheimer's disease (e.g., Donanemab, Remternetug), demonstrating a broad and active neuroscience focus.
Weight: 88
Global pharmaceutical and diagnostics company with a robust neuroscience pipeline, actively pursuing treatments for Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS), including RNAi partnerships.
Weight: 85
Direct competitor specializing in immuno-neurology, focusing on novel therapeutics for neurodegenerative diseases by modulating the immune system.